Amicus Therapeutics' GAAP loss for 3 months of 2022 was $85.26 million, up 29.8% from $65.664 million in the prior year. Revenue increased 18.5% to $78.715 million from $66.402 million a year earlier.

Amicus Therapeutics' GAAP loss for 2021 was $250.46 million, down 9.5% from $276.852 million in the previous year. Revenue increased 17.1% to $305.514 million from $260.886 million a year earlier.

Amicus Therapeutics' GAAP loss for 9M 2021 was $167.183 million, down 18.6% from $205.451 million in the prior year. Revenue increased 17.4% to $223.36 million from $190.315 million a year earlier.

Amicus Therapeutics will sell its gene therapy business to SPAC ARYA Sciences Acquisition Corp IV in exchange for 36% of its stock. ARYA will then change its name to Caritas Therapeutics and its stock will be listed on Nasdaq under the ticker symbol SPES. Amicus will retain the rights to jointly develop and commercialize Fabry and Pompe gene therapy programs...